Skip to main content
SpringerLink
Log in

Psychiatric Adverse Effects of Anticonvulsant Drugs

Incidence and Therapeutic Implications

  • Review Articles
  • Adverse Effects
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Some anticonvulsants have been reported to be associated with psychiatric adverse reactions, such as behavioural disorders, depression, mania and psychosis. However, few systematic pharmacoepidemiological studies have investigated adverse reactions to anticonvulsant drugs, which makes accurate assessment of the incidence rate of adverse drug reactions, including psychiatrie adverse reactions, very difficult. Nevertheless, by reviewing clinical trials, observational studies and case reports, it can be concluded that patients exposed to vigabatrin or phenobarbital (phenobarbitone) are at the highest risk of developing psychiatric adverse drug reactions, those exposed to phenytoin probably at medium risk, while patients exposed to carbamazepine, valproic acid (sodium valproate) and benzodiazepines are at the lowest risk. Based on the available evidence, psychiatric adverse drug reactions attributable to lamotrigine and gabapentin are relatively infrequent, although further evidence is required to confirm this. Topiramate has only been marketed for 2 years and felbamate has only had limited use because of its propensity to cause serious nonpsychiatric adverse effects; with the relative lack of peer-reviewed reports it is very difficult to comment further on the risk of psychiatrie adverse reactions to these drugs.

Rational prescribing using: (i) monotherapy, instead of polytherapy, whenever possible; (ii) the minimal effective dosage; and (iii) escalating the dosage slowly, can reduce the risk of the patient developing psychiatrie adverse drug reactions. Pre-existing psychiatric/behavioural disorders and organic brain damage are believed to predispose patients to these reactions, and such patients should be carefully monitored.

The ideal treatment of a psychiatric adverse drug reaction is discontinuation of the offending drug; however, this may not be possible for all patients with epilepsy. In cases where it is necessary to continue anticonvulsant medication to obtain satisfactory seizure control, the psychiatric disorder should be treated concurrently with psychosocial interventions and psychotropic medication, as appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lennox WG. Brain injury, drugs and environment as causes of mental decay in epilepsy. Am J Psychiatry 1942; 99: 174–80

    Google Scholar 

  2. Trimble MR, Reynolds EH. Anticonvulsant drugs and mental symptoms: a review. Psychol Med 1976; 6: 169–78

    PubMed  CAS  Google Scholar 

  3. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169–74

    PubMed  CAS  Google Scholar 

  4. Davison K, Hassanyeh F. Psychiatric disorders. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford university Press, 1981: 601–42

    Google Scholar 

  5. McClelland HA. Psychiatrie disorders. In: Davies DM. editor. Textbook of adverse drug reactions. Oxford: Oxford University Press. 1991: 549–77

    Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington. DC: American Psychiatric Association, 1994

    Google Scholar 

  8. Rawlins MD. Thompson MD. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press. 1981: 11–29

    Google Scholar 

  9. Rawlins MD, Mann RD. Monitoring adverse events and reactions. In: Mann RD. Rawlins MD. Auty RM, editors. A textbook of pharmaceutical medicine. Camforth: Parthenon Publishing Group. 1993: 317–22

    Google Scholar 

  10. Johnston SJ. Vtgabatrin and behaviour disturbances [letter]. Lancet 1990; 335: 606

    Google Scholar 

  11. Naumann M, Supprian T, Kornhuber J, et al. Bipolar affective psychosis after vigabatrin [letter]. Lancet 1994; 343: 606–7

    PubMed  CAS  Google Scholar 

  12. Landolt H. Serial EEG investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorenz de Hass AM, editor. Lectures on epilepsv. Amsterdam: Elsevier, 1958: 91–133

    Google Scholar 

  13. Tellenbach H. Epilepsie als Anfallsfeiden und als Psychose. Nervenartz 1965; 36: 190–202

    CAS  Google Scholar 

  14. Sander JWAS, Hart Y. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335: 57

    PubMed  CAS  Google Scholar 

  15. Edeh J, Toone B. Relationship between interjetai psychopathology and the type of epilepsy: results of a survey in general practice. Br J Psychiatry 1987; 151: 95–101

    PubMed  CAS  Google Scholar 

  16. Zielinski JJ. Epidemiology and medical-social problems of epilepsy in Warsaw. Final report on research program no.: 19-0-58325-F-01. Washington. DC: Warsaw Psychoneurological Institute: Social and Rehabilitation Service, 1974

    Google Scholar 

  17. Committee on Safety of Medicines. Was the drug responsible? Curr Probl Pharmacovigilance 1993; 19: 7

    Google Scholar 

  18. Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet 1955; 6885: 303–11

    Google Scholar 

  19. Wolf SM, Forsythe A, Behaviour disturbance, phenobarbital. and febrile seizures. Paediatrics 1978; 61(5): 728–31

    CAS  Google Scholar 

  20. Ferrari M, Barabas G, Matthews WS. Psychologie and behavioural disturbance among epileptic children treated with barbiturate antiepileptics. Am J Psychiatry 1983; 140(1): 112–3

    PubMed  CAS  Google Scholar 

  21. Vining EPG, Mellits ED, Dorsen MM, et al. Psychologie and behavioural effects of anti-epileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Paediatrics 1987; 80(2): 165–74

    CAS  Google Scholar 

  22. Brent DA, Crumrine PK, Varma R, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. Paediatrics 1990; 85(6): 1086–91

    CAS  Google Scholar 

  23. Brent DA, Crumrine PK, Varma R, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Paediatrics 1987; 80(6): 909–17

    CAS  Google Scholar 

  24. Domizio S, Verrotti A, Ramenghi LA, et al. Antiepileptic therapy and behaviour disturbances in children. Child Nerv Syst 1993; 9: 272–4

    CAS  Google Scholar 

  25. Mayhew LA, Hanzel TE, Kalachnik JE, et al. Phenobarbital exacerbation of self-injurious behaviour. J Nerv Ment Dis 1992; 180: 732–3

    PubMed  CAS  Google Scholar 

  26. Kugoh T, Watanabe M, Obayashi K, et al. Two cases with epilepsy who manifested manic-depressive symptoms under barbiturates treatment. Jpn J Psychiatry Neurol 1991; 45(2): 437–8

    PubMed  CAS  Google Scholar 

  27. Kugoh T, Inoue T, Utsumi T, et al. Five epileptic cases who manifested psychotic states under the toxic levels of antiepileptic drugs. Jpn J Psychiatry Neurol 1990; 44(2): 392–3

    PubMed  CAS  Google Scholar 

  28. Mattson RH, Cramer JA, Collins JF A comparison of carbamazepine, phenobarbital. Phenytoin, primidone in complex partial seizures and secondarily generalised tonic-clonic seizures. N Engl J Med 1985; 313: 145–51

    PubMed  CAS  Google Scholar 

  29. Robertson MM, Trimble MR, Townsend HRA. Phenomenology of depression in epilepsy. Epilepsia 1987; 28(4): 364–72

    PubMed  CAS  Google Scholar 

  30. Roseman E. Dilantin toxicity. Neurology 1961; 11: 912–21

    PubMed  CAS  Google Scholar 

  31. Bruni J. Phenytoin toxicity. In: Levy RH. Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 345–50

    Google Scholar 

  32. Glaser GH. Diphenylhydantoin: toxicity. In: Woodbury DM, Penry JK, Schmidt RP, editors. Antiepileptic drugs. New York: Raven Press. 1972: 219–26

    Google Scholar 

  33. Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms: a preliminary report. Br J Psychiatry 1974; 124: 440–5

    PubMed  CAS  Google Scholar 

  34. Franks RD, Richter AJ. Schizophrenia-like psychosis associated with anticonvulsant toxicity. Am J Psychiatry 1979; 136: 973–4

    PubMed  CAS  Google Scholar 

  35. McDanal CE, Bolman WM. Delayed idiosyncratic psychosis with diphenylhydantoin. JAMA 1975; 231(10): 1063

    PubMed  Google Scholar 

  36. Trimble MR. Psychiatric disorders in epilepsy. In: Shorvon SD, Dreifuss F. Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science. 1996: 337–44

    Google Scholar 

  37. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29–34

    PubMed  CAS  Google Scholar 

  38. Emrich HM, von Zerssen D, Jissling W, et al. Effects of sodium valproate in mania: the GAB A hypothesis of affective disorders. Arch Psychiatry Neurol 1980; 229: 1069–71

    Google Scholar 

  39. Gastaut H. lemolo F. Stuporous states or coma induced by the rapid administration of high doses of sodium valproate, Ital J Neurol Sci 1982; 3: 193–6

    PubMed  CAS  Google Scholar 

  40. Sackellarcs JC, Lee SI, Dreifuss EF. Stupor following administration of valproic acid to patients receiving other ami epileptic drugs. Epilepsia 1979; 20: 697–703

    Google Scholar 

  41. Rangel RJ, Warner JJ, Wilder BI. Valproate encephalopathy (abstract). Epilepsia 1987; 28(5): 605

    Google Scholar 

  42. Chadwick DW, dimming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979; 6: 552–3

    PubMed  CAS  Google Scholar 

  43. Coulter DL, Allen RJ. Secondary hyperammonemia: a possible mechanism for valproate encephalopathy [letter]. Lancet 1980; 1: 1310

    PubMed  CAS  Google Scholar 

  44. Marescaux C, Micheletti G, Warter JM, et al. Valproic de sodiu, etats stuporous et hyperammoniumie. J Med (Strasbourg) 1982; 13: 705–11

    Google Scholar 

  45. Campostrini R, Zaccara G, Rossi L, et al. Valproate-induced hyperammonemia in two epileptic identical twins. J Neurol 1985; 232: 167–8

    PubMed  CAS  Google Scholar 

  46. Salcman M. Pippenger CE. Acute carbamazepine encephalopathy [letter]. JAMA 1975; 231(9): 915

    PubMed  CAS  Google Scholar 

  47. Duche B, Louiset P, Demotes-Mainard J, et al. Encepalopathie subaigue: reaction idiosyncrasique a la carbabamazepine? Rev Neurol (Paris) 1987; 143: 211–3

    CAS  Google Scholar 

  48. Smith CR. Encephalomyelopathy as an idiosyncratic reaction to carbamazepine: a case report. Neurology 1991; 41: 760–1

    PubMed  CAS  Google Scholar 

  49. Stommel EW. Carbamazepine encephalopathy [letter]. Neurology 1992; 42: 705

    PubMed  CAS  Google Scholar 

  50. Papazian O, Canizales E, Alfonso I, et al. Reversible dementia and apparent brain atrophv during valproate therapy. Ann Neurol 1995; 38: 687–91

    PubMed  CAS  Google Scholar 

  51. Zaret BS, Cohen RA. Reversible valproic acid-induced dementia: a case report. Epilepsia 1986; 27(3): 234–40

    PubMed  CAS  Google Scholar 

  52. Armon C, Brown E, Carwile S, et al. Sensorineural hearing loss: a reversible effect of valproic acid. Neurology 1990; 40: 1896–8

    PubMed  CAS  Google Scholar 

  53. Shin C, Gray L, Armon A, et al. Reversible cerebral atrophy: radiologic correlate of valproate-induced parkinsonism dementia syndrome. Neurology 1992; 42 Suppl. 3: 277

    Google Scholar 

  54. McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci 1987; 14: 294–6

    PubMed  CAS  Google Scholar 

  55. Gehlen W, Froscher W, Bron B. Nebenwirkungen antiepileptischer Medikamente. Internist Prax 1978; 18: 333–9

    Google Scholar 

  56. Leviatov VM, Veselovskaia TD, Mar’enko GF, et al. Tegretolovye psikhozy u bolnykh shchegoleva. Ap Zh Nevgopatol Psikhiatr 1975; 75(3): 396–400

    CAS  Google Scholar 

  57. Mathew G. Psychiatric symptoms associated with carbamazepine [letter]. BMJ 1988; 296: 1071

    PubMed  CAS  Google Scholar 

  58. Mizukami K, Naito Y, Yoshida M, et al. Mental disorders induced by carbamazepine. Jpn J Psychiatry Neurol 1990; 44: 59–63

    PubMed  CAS  Google Scholar 

  59. Scull DA, Trimble MR. Mania precipitated by carbamazepine withdrawal fletter). Br J Psychiatry 1995; 167: 698

    PubMed  CAS  Google Scholar 

  60. Ketter TA. Malow BA, Flamini R. et al. Carbamazepine withdrawal-emergent psychopathology [abstract]. Neurology 1993; 43 Suppl. 2: A194

    Google Scholar 

  61. Hillbrand M, Young JL, Krystal JH. Discontinuing anticonvulsant treatment of aggression. J Neuropsychiatry Clin Neurosei 1995; 7(1): 116–7

    CAS  Google Scholar 

  62. Bellman MH, Ross EM. Side-effects of sodium valproate [letter]. BMJ 1977; 1: 1662

    Google Scholar 

  63. Carson D, Milrod L, Labar D. Psychosis from valproate intoxication [abstract]. Epilepsia 1992; 33 Suppl. 3: A194

    Google Scholar 

  64. Schmidt D. Adverse effects of valproate. Epilepsia 1984; 25 Suppl. 1: S44–9

    PubMed  Google Scholar 

  65. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994; 48(1): 25–40

    PubMed  CAS  Google Scholar 

  66. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994; 1(5): 377–87

    Google Scholar 

  67. Grohmann R, Strobcl Ch, Rüther E, et al. Adverse psychic reactions to psychotropic drugs: a report from the AMUP study. Pharmacopsychiatry 1993; 26: 84–93

    PubMed  CAS  Google Scholar 

  68. Schifano F, Magni G. Panic attacks and major depression after discontinuation of long term diazepam abuse. Ann Pharmacother 1989; 23: 989–90

    CAS  Google Scholar 

  69. Noyes R, Garvey MJ, Cook BL, et al. Benzodiazepine withdrawal: review of the evidence. J Clin Psychiatry 1988; 49: 382–9

    PubMed  Google Scholar 

  70. Khan H, Joyce P, Jones AV. Benzodiazepine withdrawal syndromes. NZ Med J 1980; 92: 94–6

    CAS  Google Scholar 

  71. White MC, Silverman JJ, Harbison JW. Psychosis associated with clonazepam therapy for blepharospasm. J Nerv Ment Dis 1982; 170(2): 117–9

    PubMed  CAS  Google Scholar 

  72. Scott DF, Moffett A. The long term effect of clobazam as adjunctive therapy in epilepsy. Acta Neurol Scand 1988; 77: 498–502

    PubMed  CAS  Google Scholar 

  73. Shorvon SD. Clobazam. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press. 1995: 763–78

    Google Scholar 

  74. Koeppen D. Clinical experience with clobazam (1968–1981). In: Hindmarch I, Stonier PD, editors. Clobazam. International Congress and Symposium Series; 43. London: Royal Society of Medicine. 1981: 193–8

    Google Scholar 

  75. Saletu B. Grunberger J, Berner P. et al. On differences between 1, 5 and 1.4 benzodiazepines: pharmaco-EEG and psychometric studies with clobazam and lorazepam. In: Hindmarch I, Stonier PD, Trimble MR, editors. Clobazam: human psychopharmacology and clinical applications. International Congress and Symposium Series; 74. London: Royal Society of Medicine, 1985: 23–46

    Google Scholar 

  76. Wolf P. Clobazam in drug-resistant patients with complex focal seizures — report of an open study. In: Hindmarch I, Stonier PD, Trimble MR. editors. Clobazam: human psychopharma-cology and clinical applications. International Congress and Symposium Series; 74. London: Royal Society of Medicine, 1985: 164–71

    Google Scholar 

  77. Fischer M, Korskjeer G, Pederson E. Psychotic episodes in Zarondan treatment. Epilepsia 1965; 6: 325–34

    PubMed  CAS  Google Scholar 

  78. Cohadon F, Loiseau P, Cohadon S. Results of treatment of certain forms of epilepsy of the petit mal type by ethosuximide. Rev Neurol 1964; 110: 201–7

    Google Scholar 

  79. Lairy CC. Psychotic signs in epileptics during treatment with ethosuximide. Rev Neurol 1964; 110: 225–6

    Google Scholar 

  80. Sato T, Kondo Y, Matsuo T, et al. Clinical experiences of ethosuximide (Zarontin) in therapy-resistant epileptics. Brain Nerve (Tokyo) 1965; 17: 958–64

    CAS  Google Scholar 

  81. Roger J, Grangeon H, Guey J, et al. Psychiatric and psychological complications of ethosuximide treatment in epileptics. Encephale 1968; 57: 407–38

    PubMed  CAS  Google Scholar 

  82. Sabers A, Dam M. Ethosuximide and methsuximide. In: Shorvon SD, Dreifuss F, Fish D. et al., editors. The treatment of epilepsy. Oxford: Blackwell Science, 1996: 414–20

    Google Scholar 

  83. Gram L, Klosterskov P, Dam M. Gamma-vinyl-GABA: a double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17: 262–6

    PubMed  CAS  Google Scholar 

  84. Loiseau P, Hardenberg JP, Pestre M, et al. Double-blind placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986; 27: 115–20

    PubMed  CAS  Google Scholar 

  85. Remy C, Favel P. Tell G. et al. Etude en double aveugle contre placebo en permutations croisees du vigabatrin dans I’epilepsie de l’adulte resistant a la therapeutique. Boll Lega Ital Epilepsy 1986: 54–55: 241–3

    Google Scholar 

  86. Rimmer EM, Richens A. A double-blind study of gamma-vinyl-GABA in patients with refractory epilepsy. Lancet 1984; 1: 189–90

    PubMed  CAS  Google Scholar 

  87. Tartara A, Manni R, Galimberli CA, et al. Vigabatrin in the treatment of epilepsy: a double-blind placebo-controlled study. Epilepsia 1986; 27: 717–23

    PubMed  CAS  Google Scholar 

  88. Tassinari CA, Michelucci R, Ambrosetto G, et al. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987; 44: 907–10

    PubMed  CAS  Google Scholar 

  89. Thomas L, Trimble M, Schmitz B. et al. Vigabatrin and behavioural disorders: a retrospective survey. Epilepsy Res 1996; 25: 21–7

    PubMed  CAS  Google Scholar 

  90. Sander JWAS, Hart YM, Trimble MR, et al. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991; 54: 235–9

    Google Scholar 

  91. Ring HA, Reynolds EH. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335: 970

    PubMed  CAS  Google Scholar 

  92. Staples CI, King MA, Boyle RS. Acute psychosis after withdrawal of vigabatrin [letter]. Med J Aust 1992; 156: 291

    PubMed  CAS  Google Scholar 

  93. Dam M. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335: 605

    Google Scholar 

  94. Betts T, Thomas L. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 336: 606

    Google Scholar 

  95. Brodie MJ, McKee PJW. Vigabatrin and behaviour disturbances [letter]. Lancet 1990; 335: 1279

    PubMed  CAS  Google Scholar 

  96. Robinson MK, Richens A, Oxley R. Vigabatrin and behavioural disturbances [letter]. Lancet 1990; 336: 504

    PubMed  CAS  Google Scholar 

  97. Krutschmann I, Duncan R. Evaluation of vigabatrin in refractory epilepsy (letter). J Neurol Neurosurg Psychiatry 1991; 54(9): 849

    PubMed  CAS  Google Scholar 

  98. Gianelli M, Camello R, Bertucci D, et al. II Fenomeno di Landolt in tre casi di epilessia farmacoresistente trattati con vigabatrin. Boll Lega Ital Epilepsy 1993; 84: 163–6

    Google Scholar 

  99. Guidolin L, Minotti L, Galletta J, et al. Psychosis associated with vigabatrin [abstract]. Epilepsia 1994; 35 Suppl. 7: 67

    Google Scholar 

  100. Jawad S, Clarke E. Richens A. Vigabatrin-induced psychosis: management problems. Seizure 1994; 3: 309–10

    PubMed  CAS  Google Scholar 

  101. Canovas-Martinez A, Ordovas-Baines JP, Beltran-Marques M, et al. Vigabatrin-associated reversible acute psychosis in a child. Ann Pharmacother 1995; 29(11): 1115–7

    PubMed  CAS  Google Scholar 

  102. Cockerell OC, Moriarty J, Trimble M, et al. Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Res 1996; 25: 119–21

    PubMed  CAS  Google Scholar 

  103. Schmidt D, Kramer G. The new anticonvulsant drugs: implications for avoidance of adverse effects. Drug Saf 1994; 11: 422–31

    PubMed  CAS  Google Scholar 

  104. Lloyd G. Psychiatry, in: Edwards CRW. Couchier RW, editors. Davidson’s principles and practices of medicine. Edinburgh: Churchill Livingstone, 1991: 929–66

    Google Scholar 

  105. Levinson DF, Mumford JP, Devinsky O. Vigabatrin and psychosis [abstract]. Epilepsia 1995; 36 Suppl. 4: 32

    Google Scholar 

  106. Ring HA, Crellin R, Kirker S, et al. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 1993; 56: 925–8

    PubMed  CAS  Google Scholar 

  107. Dijkstra JB, McGuire AM, Trimble MR. The effect of vigabatrin on cognitive function mood. Hum Psychopharmacol 1992; 7(5): 319–23

    Google Scholar 

  108. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992; 33(1): 128–34

    PubMed  CAS  Google Scholar 

  109. Piazzini A, Vignoli A, Sgro V, at al. Effects of vigabatrin on cognitive functions [abstract]. Epilepsia 1994: 35 Suppl. 7: 67

    Google Scholar 

  110. Thomas L, Trimble M. Effects of vigabatrin on cognitive function and mood in healthy volunteers [abstract]. Epilepsia 1994; 35 Suppl. 7: 67

    Google Scholar 

  111. Grunewald RA, Jackson GD, Thompson PJ, et al. Effects of vigabatrin on cognitive function [abstract]. Epilepsia 1993; 34 Suppl. 6: 78

    Google Scholar 

  112. Sastre-Garau P, Thomas P, Beaussart M, et al. Acces maniaque consecutif a une association vigabatrin-clomipramine [letter]. Encephale 1994; 203: 363

    Google Scholar 

  113. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889–926

    PubMed  CAS  Google Scholar 

  114. Aldenkamp AP, Vermeulen OG, Mulder JO, et al. Gamma-vinyl GABA (vigabatrin) and mood disturbances. Epilepsia 1994; 35: 999–1004

    PubMed  CAS  Google Scholar 

  115. Wong ICK. Retrospective study of vigabatrin and psychiatric/behavioural disturbances. Epilepsy Res 1995; 21(3): 227–30

    PubMed  CAS  Google Scholar 

  116. Sharif MK, Sander JWAS, Shorvon SD. Acute encephalopathy with vigabatrin [letter]. Lancet 1993; 342: 619

    Google Scholar 

  117. Salke-Kellermann A, Baier H, Rambeck B, et al. Acute encephalopathy with vigabatrin [letter]. Lancet 1993; 342: 185

    PubMed  CAS  Google Scholar 

  118. Sivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32(4): 539–42

    PubMed  CAS  Google Scholar 

  119. US Gabapentin Study Group. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled. parallel-group study. Neurology 1993; 43: 2292–8

    Google Scholar 

  120. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114–7

    Google Scholar 

  121. Anhut H, Ashman P, Feuerstein TJ, et al. The International Gabapentin Study Group. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35(40): 795–801

    PubMed  CAS  Google Scholar 

  122. US Gabapentin Study Group. Long term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994; 18(1): 67–73

    Google Scholar 

  123. Short C, Cook L. Hypomania induced by gabapentin. Br J Psychiatry 1995; 166: 679–80

    PubMed  CAS  Google Scholar 

  124. Doherty KP, Gates JR, Penovich PE, et al. Gabapentin in a medically refractory epilepsy population: seizure response and unusual side-effects [abstract]. Epilepsia 1995; 36 Suppl. 4: 71

    Google Scholar 

  125. Litzinger MJ, Wiscombe N, Hanny A, et al. Increased seizures and aggression seen in persons with mental retardation and epilepsy treated with neurontin [abstract]. Epilepsia 1995; 36 Suppl. 4: 71

    Google Scholar 

  126. Lee DO, Steingard RJ, Cesena M, et al. Behavioural side effects of gabapentin in children. Epilepsia. 1996; 37(1): 87–90

    PubMed  CAS  Google Scholar 

  127. Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifestine as behavioural changes. Epilepsia. 1995; 36(12): 1203–5

    PubMed  CAS  Google Scholar 

  128. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222–9

    PubMed  CAS  Google Scholar 

  129. Jawad S, Richens A, Goodwin G, el al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989; 30: 356–63

    PubMed  CAS  Google Scholar 

  130. Loiseau P, Yuen AWC, Duche B, et al. A randomised doubleblind, placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990; 7: 136–45

    PubMed  CAS  Google Scholar 

  131. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993; 43: 2284–91

    PubMed  CAS  Google Scholar 

  132. Messenheimer J, Ramsay RE, Willmorc LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35(1): 113–21

    PubMed  CAS  Google Scholar 

  133. Sander Jr WAS, Patsalos PN, Oxley JR, et al. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990; 6: 221–6

    PubMed  CAS  Google Scholar 

  134. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56: 448–53

    PubMed  CAS  Google Scholar 

  135. Smith D, Baker GA, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312–22

    PubMed  CAS  Google Scholar 

  136. Richens A. Safety of lamotrigine. Epilepsia 1994; 35 Suppl. 5: S37–40

    PubMed  Google Scholar 

  137. Committee on Safety of Medicines. Lamotrigine (Lamictal). Curr Probi Pharmacovigilance 1993; 19: 3–4

    Google Scholar 

  138. Martin M. Munoz-Blanco JL, Lopez-Ariztegui N. Acute psychosis induced by lamotrigine [abstract]. Epilepsia 1995: 36 Suppl. 3: S118

    Google Scholar 

  139. Hennessy MJ, Wiles CM. Lamotrigine encephalopathy [letter]. Lancet 1995; 347: 974–5

    Google Scholar 

  140. Kilpatrick ES, Forrest G, Brodie M. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996; 37(6): 534–8

    PubMed  CAS  Google Scholar 

  141. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, et al. The efficacy and long term tolcrability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990; 7: 226–9

    PubMed  CAS  Google Scholar 

  142. Reife RA. Topiramate. In: Shorvon SD, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science. 1996. 471–81

    Google Scholar 

  143. Topamax data sheet. High Wycombe: Janssen-Cilag, 1996

  144. Ahmad SR. Felbamate and aplastic anaemia. Lancet 1994; 344: 463

    Google Scholar 

  145. Bebin EM, Sofia RD, Dreifuss FE. Felbamate toxicity. In: Levy RH, Mattson RH, Meldrum BS. editors. Anticpileptic drugs. 4th ed. New York: Raven Press. 1995: 823–7

    Google Scholar 

  146. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45(6): 1041–65

    PubMed  CAS  Google Scholar 

  147. Wagner ML. Felbamate: a new antiepileptic drug. Am J Hosp Pharm 1994; 51(13): 1657–66

    PubMed  CAS  Google Scholar 

  148. Taloxa: safety and tolerability. Taloxa product monograph. Kenilworth (NJ): Schering-Plough, 1995: 28-33

  149. Wilder BJ, Campbell KW, Uthman BM, et al. Felbamate for intractable epilepsy: a long term study labstracll. Epilepsia 1991; 32 Suppl. 3: 59

    Google Scholar 

  150. Theodore WH, Albert P, Stertz B, et al. Felbamate monotherapy: implications for antiepileptic drug development. Epilepsia 1994; 36(11): 1105–10

    Google Scholar 

  151. Knable MB, Rickler K. Psychosis associated with felbamate treatment. J Clin Psychopharmacol 1995; 15(4): 292–3

    PubMed  CAS  Google Scholar 

  152. Kanner AM, Ristanovic R, Smith M, et al. Acute depressive disorder following a three week switch-over to felbamate: a controlled study labstractl. Epilepsia 1994; 35 Suppl. 8: 95

    Google Scholar 

  153. Hill RR, Stagno SJ, Tesar GE. Secondary mania associated with the use of felbamate. Psychosomatics 1995; 36(4): 404–6

    PubMed  CAS  Google Scholar 

  154. King JA. Increased incidence of adverse behavioural side effects associated with the addition of felbamate (FBM) to antiepileptic drug (AED) regimens in the mentally retarded (MR) population [abstract]. Epilepsia 1994; 35 Suppl. 8: 94

    Google Scholar 

  155. Bazire S. Psychotropics in problem areas. Psychotropic drug directory. Salisbury: Mark Allen Publishing Ltd. 1995: 91–120

    Google Scholar 

  156. Central nervous system. In: British national formulary. London: British Medical Association, Royal Pharmaceutical Society of Great Britain. 1997; 33: 152–223

    Google Scholar 

  157. Toone BK, Fenton GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977; 7: 265–70

    PubMed  CAS  Google Scholar 

  158. Clozaril data sheet. Camberley: Sandoz, 1997

  159. Neppe VM, Tucker GJ. Neuropsychiatie aspects of seizure disorders. In: Yudofsky SC, Hales RE, editors. Textbook of neuropsychiatry. 2nd ed. Washington, DC: American Psychiatric Press. 1992: 387–425

    Google Scholar 

  160. Richens A, Nawishy S, Trimble M. Antidepressant drugs, convulsions and epilepsy. Br J Clin Pharmacol 1983; 15: 295S–8S

    PubMed  Google Scholar 

  161. Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8

    PubMed  CAS  Google Scholar 

  162. Harmant J, Van Rijckevorsel-Harmant K, De Barsy TH, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect [letter]. Lancet 1990; 336: 386

    PubMed  CAS  Google Scholar 

  163. Perucca E, Richens A. Interaction between Phenytoin and Imipramine. Br J Clin Pharmacol 1977; 4: 485–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, University of Bradford, Bradford, West Yorkshire, BD7 1DP, England

    Ian C. K. Wong

  2. Academic Department of Psychiatry, Queens Medical Centre, University Hospital, Nottingham, England

    Simon J. Tavernor

  3. University Department of Psychiatry, Royal Liverpool University Hospital, Liverpool, England

    Rosalyn M. E. Tavernor

Authors
  1. Ian C. K. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon J. Tavernor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosalyn M. E. Tavernor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, I.C.K., Tavernor, S.J. & Tavernor, R.M.E. Psychiatric Adverse Effects of Anticonvulsant Drugs. CNS Drugs 8, 492–509 (1997). https://doi.org/10.2165/00023210-199708060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199708060-00006

Keywords

Search

Navigation